Regeneron rises on deal to buy 23andMe for $256 million
Shares of drugmaker Regeneron Pharmaceuticals REGN.O rise 2% to $606 premarket
REGN says it has agreed to buy bankrupt genetic testing firm 23andMe Holding for $256 million
The agreement excludes the purchase of 23andMe's telehealth service Lemonaid Health
23andMe's bankruptcy proceedings had drawn scrutiny from lawmakers who warned that genetic data of millions of customers could be sold to unscrupulous buyers
Regeneron says it will comply with 23andMe's privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer
As of last close, REGN down 16.6% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey






